Elsevier

European Journal of Cancer

Volume 84, October 2017, Pages 114-120
European Journal of Cancer

Original Research
Risk of uterine cancer for BRCA1 and BRCA2 mutation carriers

https://doi.org/10.1016/j.ejca.2017.07.004Get rights and content

Highlights

  • Five cases of uterine cancers were reported in 828 BRCA1 and BRCA2 mutation carriers.

  • Three of the five affected women had previous tamoxifen treatment for breast cancer.

  • The standardised incidence ratio for uterine cancer in mutation carriers was 2.45 (95% confidence interval: 0.80–5.72; P = 0.11).

  • There were no cases of the serous subtype of uterine cancer in this study.

  • These data do not justify risk-reducing hysterectomy in BRCA1 and BRCA2 mutation carriers.

Abstract

Background

Whether BRCA1 and BRCA2 mutation carriers have a clinically relevant elevated risk of uterine cancer has implications for risk-reducing surgery.

Aim

This multicentre, prospective cohort study assessed uterine cancer risk for mutation carriers compared with the general population.

Methods

Eligible mutation carriers were enrolled in the Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer (kConFab) cohort study, had a uterus present and no history of uterine cancer at cohort entry. Epidemiological, lifestyle and clinical data were collected at cohort entry and updated three-yearly. Cancer events were verified using pathology reports. Follow-up was censored at death or last contact. Relative risk of uterine cancer was estimated using the standardised incidence ratio (SIR), with the expected number of cases determined using population-based data for Australia.

Results

Of 1,111 mutation carriers in kConFab, 283 were excluded due to prior hysterectomy (N = 278), prior uterine cancer (N = 2) or being non-residents (N = 3). After a median follow-up of 9.0 years, five incident uterine cancers were reported in the 828 eligible women (419 had prior breast cancer and 160 had prior tamoxifen use), compared to 2.04 expected (SIR = 2.45; 95% confidence interval [CI]: 0.80–5.72; P = 0.11). In 438 BRCA1 mutation carriers and 390 BRCA2 mutation carriers, three and two incident cases of uterine cancer were reported, respectively, compared to 1.04 expected (SIR = 2.87; 95% CI: 0.59–8.43; P = 0.18) and 0.99 expected (SIR = 2.01; 95% CI: 0.24–7.30; P = 0.52), respectively. All cases were endometrioid subtype, International Federation of Gynaecology and Obstetrics stage I–II disease. No serous uterine cancers were reported.

Conclusions

Our findings are consistent with those from most other reports and do not support routine risk-reducing hysterectomy for BRCA1 and BRCA2 mutation carriers.

Introduction

Women carrying a deleterious germline BRCA1 or BRCA2 mutation are recommended to undergo risk-reducing salpingo-oophorectomy (RRSO) by peak bodies, such as the United States National Comprehensive Cancer Network [1] and Cancer Australia [2]. This is due to the established elevated risk of high grade pelvic serous cancer in these women, with a lifetime cumulative risk ranging from 6% to 54% [3], [4], [5], [6]. RRSO is associated with an 85% reduced risk of pelvic serous cancer in mutation carriers [7], [8], [9] and reduced cancer-specific and all-cause mortality [7], [10]. The term ‘pelvic serous cancer’ is used because the majority of BRCA1 and BRCA2 mutation-associated gynaecologic cancers (ovarian, fallopian tube or primary peritoneal) appear to arise from the fallopian tube fimbriae rather than the ovary, although they have often been labelled as ‘ovarian cancer’ at diagnosis [11], [12], [13].

An ongoing area of controversy is whether risk-reducing hysterectomy should be performed at the time of RRSO [14], [15]. The risk of uterine cancer for BRCA1 and BRCA2 mutation carriers remains unclear with conflicting findings in different studies possibly confounded by prior tamoxifen use. Although, most studies have suggested about a two-fold increase in risk relative compared to the general population [16], [17], [18], [19], the findings were statistically significant in only two of these studies [16], [17]. A recent study suggested a much higher relative risk (RR) but only when the analysis was limited to the serous uterine cancer subtype and the finding was only statistically significant for BRCA1 mutation carriers [19].

Performing abdominal hysterectomy in conjunction with RRSO is associated with higher risk of complications compared to RRSO alone, although the complications are less with minimally invasive surgery [20], [21]. Therefore, a more precise estimate of the incidence and RR of uterine cancer for BRCA1 and BRCA2 mutation carriers would help guide clinicians in weighing up risk-reduction benefits against the peri-operative and long-term morbidity [22]. We sought to assess, using data from a prospective cohort study, whether BRCA1 and BRCA2 mutation carriers are at increased risk of developing uterine cancer compared to the general population. If mutation carriers are at significantly increased risk of developing uterine cancer, there may be an added benefit of prophylactic hysterectomy at the time of RRSO.

Section snippets

Participants

Eligible women were a subset of females enrolled in the Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer (kConFab), a resource of data and biospecimens from multiple-case breast and ovarian cancer families [23], [24], [25]. Eligibility criteria for kConFab are detailed on the website [23]. Families are recruited via 24 familial cancer clinics in Australia and New Zealand. At enrolment, blood is drawn for BRCA1 and BRCA2 mutation analysis.

Women were included in

Results

A total of 1,111 BRCA1 and BRCA2 mutation carriers with systematic prospective follow-up were identified. Of those, 283 women (25%) were excluded as they had hysterectomy (for non-malignant reasons) before cohort entry (N = 278), prior history of uterine cancer (N = 2) or they did not reside in Australia or New Zealand (N = 3). The remaining 828 women, 438 (53%) BRCA1 mutation carriers and 390 (47%) BRCA2 mutation carriers, were prospectively followed from cohort entry for a median of 9.0 years.

Discussion

Our study investigated the incidence of uterine cancer for BRCA1 and BRCA2 mutation carriers residing in Australia and New Zealand. Compared to the general population, women with a deleterious BRCA1 or BRCA2 mutation had about 2.5-fold increased risk of developing uterine cancer, although this was not statistically significant. More specifically the SIR was 2.87 for BRCA1 mutation carriers and 2.01 for BRCA2 mutation carriers. This finding is consistent with the literature which generally

Role of funding

This work was supported by grants to kConFab and the kConFab Follow-Up Study from Cancer Australia [grant number 809195], the Australian National Breast Cancer Foundation [grant number IF 17 kConFab], the National Health and Medical Research Council [grant numbers 454508, 288704, 145684], the National Institute of Health U.S.A. [grant number 1RO1CA159868], the Queensland Cancer Fund, the Cancer Councils of New South Wales, Victoria, Tasmania and South Australia and the Cancer Foundation of

Conflict of interest statement

None declared.

Acknowledgements

The authors thank Heather Thorne, Eveline Niedermayr, all the kConFab research nurses and staff, the heads and staff of the Family Cancer Clinics and the many families who contribute to kConFab for their contributions to this resource.

References (40)

  • L. Bergman et al.

    Risk and prognosis of endometrial cancer after tamoxifen for breast cancer. Comprehensive Cancer Centres' ALERT Group. Assessment of liver and endometrial cancer risk following tamoxifen

    Lancet

    (2000)
  • H. Mahdi et al.

    Racial disparity in survival of patients with uterine serous carcinoma: changes in clinical characteristics, patterns of care and outcomes over time from 1988 to 2011

    Gynecol Oncol

    (2016)
  • P.E. Goss et al.

    National Cancer Institute of Canada Clinical Trials Group MAP.3 Trial: evaluation of exemestane to prevent breast cancer in postmenopausal women

    Clin Breast Cancer

    (2007)
  • J. Cuzick et al.

    Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial

    Lancet

    (2014)
  • J.F. Forbes et al.

    Anastrozole versus tamoxifen for the prevention of locoregional and contralateral breast cancer in postmenopausal women with locally excised ductal carcinoma in situ (IBIS-II DCIS): a double-blind, randomised controlled trial

    Lancet

    (2016)
  • M.B. Daly et al.

    Genetic/familial high-risk assessment: breast and ovarian

    J Natl Compr Canc Netw

    (2016)
  • Cancer Australia

    Recommendations for management of women at high risk of ovarian cancer

    (2011)
  • R.M. Brohet et al.

    Breast and ovarian cancer risks in a large series of clinically ascertained families with a high proportion of BRCA1 and BRCA2 Dutch founder mutations

    J Med Genet

    (2014)
  • J.M. Satagopan et al.

    Ovarian cancer risk in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations

    Clin Cancer Res

    (2002)
  • K.B. Kuchenbaecker et al.

    Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers

    JAMA

    (2017)
  • Cited by (0)

    g

    Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, Australia.

    i

    Research Department, Peter MacCallum Cancer Centre, Melbourne, Australia.

    View full text